PDF herunterladen
Thromb Haemost 1997; 78(06): 1505-1509
DOI: 10.1055/s-0038-1665442
Rapid Communication
Schattauer GmbH Stuttgart

Erythropoietin Administration Increases Production and Reactivity of Platelets in Dogs

Roman F Wolf
The Department of Medicine and W. K. Warren Medical Research Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
,
Jinpeng Peng
The Department of Medicine and W. K. Warren Medical Research Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
,
Paul Friese
The Department of Medicine and W. K. Warren Medical Research Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
,
Laura S Gilmore
The Department of Medicine and W. K. Warren Medical Research Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
,
Samuel A Burstein
The Department of Medicine and W. K. Warren Medical Research Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
,
George L Dale
The Department of Medicine and W. K. Warren Medical Research Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 11. 1997

Accepted 11. Juli 1997

Publikationsdatum:
12. Juli 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

Administration of erythropoietin (EPO) to adult dogs resulted in a dramatic increase in the number of thiazole orange-positive (TO+) platelets, also referred to as reticulated platelets. Pre-treatment level of TO+ platelets was 6.2 ± 0.5% (mean ± 1 SE; n = 5); following day 5 of treatment with 500 U EPO/kg/day, the percentage of TO+ platelets peaked at 16.8 ± 2.3% (n = 5; p <0.02). After cessation of the hormone, the number of TO+ platelets fell rapidly to below starting levels. Unexpectedly, there was a significant decline in total platelet count during EPO administration despite an increased level of TO+ platelets. To assess platelet reactivity, total platelets and TO+ platelets from EPO- treated dogs were analyzed for thrombin-responsiveness as quantitated by P-selectin expression on the cell surface; reactivity was expressed as a thrombin EC50, the thrombin concentration required to activate 50% of platelets. Both total and TO+ platelets were hyperreactive during EPO treatment when compared either to pre-treatment values or to control animals. Thrombin EC50 values for total and TO+ platelets on day 5 fell to 66.5 ± 5.4% (mean ± 1 SE; n = 5; p <0.02) and 62.2 ± 8.7% (n = 5; p <0.025), respectively, of pre-treatment levels. These data indicate that EPO not only promotes the synthesis of increased numbers of TO+ platelets in the dog but that these newly produced platelets are hyperreactive when compared to TO+ platelets from control animals.

 

  • References

  • 1 Krantz SB. Erythropoietin. Blood 1991; 77: 419-434
    CrossrefPubMedSuche in Google Scholar
  • 2 Ishibashi T, Koziol JA, Burstein SA. Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J Clin Invest 1987; 79: 286-289
    CrossrefPubMedSuche in Google Scholar
  • 3 Papayannopoulou T, Brice M, Farrer D, Kaushansky K. Insights into the cellular mechanisms of erythropoietin-thrombopoietin synergy. Exp Hematol 1996; 24: 660-669
    PubMedSuche in Google Scholar
  • 4 Fraser JK, Tan AS, Lin FK, Berridge MV. Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp Hematol 1989; 17: 10-16
    PubMedSuche in Google Scholar
  • 5 Berridge MV, Fraser JK, Carter JM, Lin FK. Effects of recombinant human erythropoietin on megakaryoctyes and on platelet production in the rat. Blood 1988; 72: 970-977
    PubMedSuche in Google Scholar
  • 6 Tsukada J, Misago M, Kikuchi M, Sato T, Ogawa R, Oda S, Chiba S, Eto S. The effect of high doses of recombinant human erythropoietin on megakaryocytopoiesis and platelet production in splenectomized mice. Br J Haematol 1990; 76: 260-268
    CrossrefPubMedSuche in Google Scholar
  • 7 Shikama Y, Ishibashi T, Kimura H, Kawaguchi M, Uchida T, Maruyama Y. Transient effect of erythropoietin on thrombocytopoiesis in vivo in mice. Exp Hematol 1992; 20: 216-222
    PubMedSuche in Google Scholar
  • 8 Pirisi M, Fabris C, Soardo G, Cecchin E, Toniutto P, Bartoli E. Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment. J Hepatology 1994; 21: 376-380
    CrossrefPubMedSuche in Google Scholar
  • 9 Sharpe PC, Desai ZR, Morris TCM. Increase in mean platelet volume in patients with chronic renal failure treated with erythropoietin. J Clin Pathol 1994; 47: 159-161
    CrossrefPubMedSuche in Google Scholar
  • 10 Van Geet C, Hauglustaine D, Verresen L, Vanrusselt M, Vermylen J. Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients. Thromb Haemost 1989; 61: 117-121
    Thieme ConnectPubMedSuche in Google Scholar
  • 11 Malyszko J, Malyszko JS, Borawski J, Rydzewski A, Kalinowski M, Azzadin A, Mysliwiec M, Buczko W. A study of platelet functions some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 1995; 77: 133-143
    CrossrefPubMedSuche in Google Scholar
  • 12 Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies. Blood 1987; 70: 307-315
    PubMedSuche in Google Scholar
  • 13 Johnston GI, Pickett EB, McEver RP, George JN. Heterogeneity of platelet secretion in response to thrombin demonstrated by fluorescence flow cytometry. Blood 1987; 69: 401-403
    PubMedSuche in Google Scholar
  • 14 Peng J, Friese P, Wolf RF, Harrison P, Downs T, Lok S, Dale GL, Burstein SA. Relative reactivity of platelets from thrombopoietin- and interleukin-6-treated dogs. Blood 1996; 87: 4158-4163
    PubMedSuche in Google Scholar
  • 15 Dale GL, Friese P, Hynes LA, Burstein SA. Demonstration that thiazole orange-positive platelets in the dog are less than twenty-four hours old. Blood 1995; 85: 1822-1825
    PubMedSuche in Google Scholar
  • 16 Peng J, Friese P, Heilmann E, George JN, Burstein SA, Dale GL. Aged platelets have an impaired response to thrombin as quantitated by P-selectin expression. Blood 1994; 83: 161-166
    PubMedSuche in Google Scholar
  • 17 Burstein SA, Friese P, Downs T, Epstein RE. Canine megakaryocytopoiesis: Analysis utilizing a monoclonal antibody to a 140 kD dog platelet protein. Exp Hematol 1991; 19: 47-52
    PubMedSuche in Google Scholar
  • 18 Ault KA, Rinder HM, Mitchell J, Carmody MB, Vary CPH, Hillman RS. The significance of platelets with increased RNA content (reticulated platelets). Am J Clin Pathol 1992; 98: 637-646
    CrossrefPubMedSuche in Google Scholar
  • 19 Lee LG, Chen CH, Chiu LA. Thiazole orange: A new dye for reticulocyte analysis. Cytometry 1986; 7: 508-517
    CrossrefPubMedSuche in Google Scholar
  • 20 Eschbach JW, Abudulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbert S, Krantz SB, Lundin AP, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ, Teschan P, Van Stone JC, Van Wyck DB, Zuckerman K, Adamson JW. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Ann Int Med 1989; 111: 0992-1000
    CrossrefPubMedSuche in Google Scholar
  • 21 Taylor JE, Belch JJ, Henderson IS, Stewart WK. Erythropoietin does not increase whole blood platelet aggregation in vitro. Nephrology, Dialysis, Transplantation 1993; 8: 556-558
    PubMedSuche in Google Scholar
  • 22 McDonald TP, Clift RE, Cottrell MB. Large, chronic doses of erythropoietin cause thrombocytopenia in mice. Blood 1992; 80: 352-358
    PubMedSuche in Google Scholar
  • 23 Wolf RF, Gilmore LS, Friese P, Downs T, Burstein SA, Dale GL. Erythropoietin potentiates thrombus development in a canine arterio-venous shunt model. Thromb Haemost 1997; 77: 1020-1024
    Thieme ConnectPubMedSuche in Google Scholar
  • 24 Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD. Pharmacokinetics of intravenous intraperitoneal and subcutaneous recombinant erythropoietin in patients with CAPD. Contrib Nephrol 1989; 76: 112-121
    PubMedSuche in Google Scholar
  • 25 Erslev AJ, Wilson J, Caro J. Erythropoietin titers in anemic nonuremic patients. J Lab Clin Med 1987; 109: 429-433
    PubMedSuche in Google Scholar
  • 26 Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatrics 1992; 120: 360-366
    CrossrefPubMedSuche in Google Scholar
  • 27 Palek J, Jarolim P. Hereditary spherocytosis elliptocytosis and related disorders. In: Williams Hematology Beutler E, Lichtman MA, Coller BS, Kipps TJ. (eds) 5. McGraw-Hill; New York: 1995. pp 536-557
    Suche in Google Scholar
  • 28 Hirsh J, Dacie JV. Persistent post-splenectomy thrombocytosis and thromboembolism: A consequence of continuing anaemia. Br J Haematol 1966; 12: 44-53
    CrossrefPubMedSuche in Google Scholar
  • 29 Lipski DA, Bergamini TM. Upper extremity arterial thrombosis associated with immunohemolytic anemia. Surgery 1996; 119: 354-355
    CrossrefPubMedSuche in Google Scholar
  • 30 Brown AS, Martin JF. The megakaryocyte platelet system and vascular disease. Eur J Clin Invest 1994; (Suppl. 24) 1: 09-15
    PubMedSuche in Google Scholar
  • 31 Harker LA, Hanson SR. Platelet factors predisposing to arterial thrombosis. Bailliere’s Clin Haematol 1994; 7: 499-522
    CrossrefPubMedSuche in Google Scholar